Back to Search Start Over

Mayo Clinic Tapestry Study: A Large-Scale Decentralized Whole Exome Sequencing Study for Clinical Practice, Research Discovery, and Genomic Education.

Authors :
Bandel LA
Vierkant RA
Kruisselbrink TM
Bublitz ML
Wilson TA
Armasu SM
Egan JB
Presutti RJ
Samadder NJJ
Sekulic A
Olson RJ
Tan-Arroyo J
Morales-Rosado JA
Klee EW
Ferber MJ
Kemppainen JL
Anderson JL
Bidwell JS
Wick JJ
Ortega VE
Bobo WV
Pichurin PN
Mcmillan JM
Weaver DM
Riegert-Johnson DL
Cera AM
Boucher LM
Kullo IJ
Mantia SK
Jones MT
Larson NB
Luehrs TC
Leitzke JW
Sicotte H
Tian S
Stavlund JR
Pacyna JE
Sharp RR
Asabere AA
Lu J
McAllister TM
Walker TS
Stewart AK
Farrugia G
Lazaridis KN
Source :
Mayo Clinic proceedings [Mayo Clin Proc] 2024 Nov 05. Date of Electronic Publication: 2024 Nov 05.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Objective: To execute a large-scale, decentralized, clinical-grade whole exome sequencing study, coined Tapestry, for clinical practice, research discovery, and genomic education.<br />Patients and Methods: Between July 1, 2020, and May 31, 2024, we invited 1,287,608 adult Mayo Clinic patients to participate in Tapestry. Of those contacted, 114,673 patients were consented and 98,222 (65.2% women) are currently enrolled: 62,495 (63.6%) were recruited from Minnesota-, 18,353 (18.7%) from Florida- and 17,374 (17.7%) from Arizona-based practices. Saliva from participants was used to extract DNA, and whole exome sequencing plus ∼300,000 single nucleotide polymorphisms (ie, Exome+ assay) were sequenced by a clinical lab. Results for the Centers for Disease Control and Prevention Tier 1 genes (eg, hereditary breast, ovarian cancer syndrome: BRCA1/2; Lynch syndrome: MLH1, MSH2, MSH6, PMS2, and EPCAM; and familial hypercholesterolemia: APOB, LDLR, PCSK9, and LDLRAP1) were interpreted and entered into the electronic health record.<br />Results: The median age of participants was 59.1 years and ∼11% were from racial/ethnic groups under-represented in research. One thousand eight hundred nineteen (1.9%) participants had actionable pathogenic or likely pathogenic variants (50.0% BRCA1/2, 28.4% familial hypercholesterolemia, and 22.2% Lynch syndrome). Positive results were communicated by genetic counselors who educated patients and providers. Thus far, 62,758 patients' Exome+ assays are stored for research, and the Tapestry Data Access Committee has received 118 requests from investigators, of which 82 have been approved, resulting in the delivery of 1,117,410 Exome+ assays to researchers.<br />Conclusion: A large, decentralized, clinical Exome+ assay study in a tertiary medical center detects actionable germline variants, educates patients as well as providers, and offers access to big data for discovery that advances human health.<br />Trial Registration: clinicaltrials.gov Identifier: NCT05212428.<br /> (Copyright © 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1942-5546
Database :
MEDLINE
Journal :
Mayo Clinic proceedings
Publication Type :
Academic Journal
Accession number :
39625429
Full Text :
https://doi.org/10.1016/j.mayocp.2024.08.005